论文部分内容阅读
目的:miRNA遍及生命体的发生、发育、分化和死亡的过程。它在肿瘤、心血管、糖尿病等多种疾病的各个阶段中起到调控癌基因作用。miRNA在垂体腺瘤中异常表达,且影响垂体腺瘤的增殖、侵袭及凋亡情况。本研究通过探讨miRNA家族中的miR-26a在垂体腺瘤组织及血清中的表达变化情况,为垂体瘤的早期诊断及疗效监测提供依据,以便更好的指导临床诊断及治疗工作。方法:收集哈尔滨医科大学附属第四医院微创神经外科手术切除并经病理证实的垂体腺瘤20例,取其组织及采集血清标本;年龄在20~74岁(平均50岁),术前均未进行任何治疗。既往无内分泌疾病的正常死亡人的垂体组织及其血清标本20例作为对照组。采用实时定量聚合酶链式反应(Real-time PCR)方法分别检测垂体腺瘤病人和正常人组织及血清中的miRNA-26a的表达情况。用SPSS13.0统计分析软件运用Mann-Whitney U检验方法对数据进行统计学分析。结果:miRNA-26a在垂体腺瘤组织中的表达量为22.30,正常垂体组织中的表达量为23.38,垂体腺瘤患者血清中miRNA-26a的表达表达量为25.04,正常对照组血清中的表达量为24.95,垂体腺瘤组织中的表达较正常垂体组织中的表达明显升高(P<0.05),垂体腺瘤患者血清与正常人血清中miRNA-26a的表达无明显差异(P>0.05)。结论:垂体腺瘤组织中miRNA-26a的高表达与血清学检测miRNA-26a的正常表达,为预防脑垂体腺瘤的发生和发展提供了重要的临床诊断依据。
Objective: miRNA spread throughout the life of the body, development, differentiation and death process. It plays a role in regulating oncogenes in all stages of cancer, cardiovascular, diabetes and other diseases. MiRNAs are abnormally expressed in pituitary adenomas and affect the proliferation, invasion and apoptosis of pituitary adenomas. In this study, we investigated the expression changes of miR-26a in pituitary adenoma tissue and serum in miRNA family and provided the basis for the early diagnosis and therapeutic effect of pituitary adenoma in order to better guide the clinical diagnosis and treatment. Methods: 20 cases of pituitary adenomas resected and pathologically confirmed by minimally invasive neurosurgery in the Fourth Affiliated Hospital of Harbin Medical University were collected. Tissues and serum samples were collected from 20 to 74 years old (mean 50 years) No treatment was given. In the past, there were 20 cases of pituitary tissue and serum samples of normal death without endocrine disease as control group. Real-time PCR was used to detect the expression of miRNA-26a in the tissue and serum of pituitary adenoma patients and normal people respectively. Statistical analysis was performed using the Mann-Whitney U test using SPSS 13.0 statistical analysis software. Results: The expression of miRNA-26a in pituitary adenomas was 22.30, that in normal pituitary tissues was 23.38, that of miRNA-26a in pituitary adenoma was 25.04, and that in normal control group The expression of miRNA-26a in pituitary adenoma tissues was significantly higher than that in normal pituitary tissues (P <0.05), and the expression of miRNA-26a in serum of pituitary adenoma patients was no significant difference (P> 0.05) . Conclusion: The high expression of miRNA-26a and the normal expression of miRNA-26a in pituitary adenoma tissue provide an important clinical diagnosis basis for preventing the occurrence and development of pituitary adenoma.